Tokorozawa, Japan

Akihiro Haruno

This inventor holds 1 USPTO granted patent. Top assignee: Taiho Pharmaceutical Company Limited. Active years: 2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Akihiro Haruno. Retrieved from https://idiyas.com/inventor/akihiro-haruno

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 52(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Akihiro Haruno: Innovator in Prostatic Research

Introduction

Akihiro Haruno is a notable inventor based in Tokorozawa, Japan. He has made significant contributions to the field of medical research, particularly in the area of prostatic health. His innovative work has led to the development of a unique animal model that aids in the understanding and treatment of benign prostatic hyperplasia.

Latest Patents

Haruno holds a patent for an "Interstitial prostatism model animal." This invention provides an animal model for prostatic stromal hyperplasia, which is crucial for screening substances that may prevent or treat human benign prostatic hyperplasia. The model is created by implanting the fetal urogenital sinus of a non-human animal, allowing researchers to measure the effects of test substances on the implanted tissue.

Career Highlights

Haruno is associated with Taiho Pharmaceutical Company Limited, where he continues to advance his research and innovations. His work is pivotal in developing effective treatments for conditions affecting prostate health.

Collaborations

He has collaborated with notable colleagues, including Nobuyuki Oda and Kazuhisa Miyoshi, to further enhance the impact of his research.

Conclusion

Akihiro Haruno's contributions to medical research, particularly through his patented animal model, highlight his role as an innovator in the field. His work not only advances scientific understanding but also paves the way for potential treatments for benign prostatic hyperplasia.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…